RFXANK and combined immunodeficiency: The MENA registry also reported high mortality in non-syndromic combined immunodeficiencies (51.7%) and syndromic CID (22.5%), particularly in patients with RFXANK, RAG1, and IL2RG mutations, where the most common causes of death were infection and respiratory failure [29].